# Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

> **NCT03063710** · — · NO_LONGER_AVAILABLE · sponsor: **AstraZeneca**

## Conditions studied

- PSR Ovarian Cancer With a BRCA Mutation

## Interventions

- **DRUG:** olaparib

## Key facts

- **NCT ID:** NCT03063710
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03063710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03063710, "Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03063710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*